2004
DOI: 10.1016/j.jconrel.2003.11.018
|View full text |Cite
|
Sign up to set email alerts
|

Drug, enzyme and peptide delivery using erythrocytes as carriers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
97
0
4

Year Published

2007
2007
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 172 publications
(108 citation statements)
references
References 119 publications
4
97
0
4
Order By: Relevance
“…Owing to their biocompatibility, EGs have been studied for use as vehicles for delivering various biologically active substances, including chemical drugs, enzymes and peptides [10][11][12]. Our previous study showed that EGs can be used as an in vivo delivery system for plasmid DNA [5], and others have used EGs to encapsulate peptide nucleic acid (PNA) for delivery into macrophages in vitro [13].…”
Section: Discussionmentioning
confidence: 99%
“…Owing to their biocompatibility, EGs have been studied for use as vehicles for delivering various biologically active substances, including chemical drugs, enzymes and peptides [10][11][12]. Our previous study showed that EGs can be used as an in vivo delivery system for plasmid DNA [5], and others have used EGs to encapsulate peptide nucleic acid (PNA) for delivery into macrophages in vitro [13].…”
Section: Discussionmentioning
confidence: 99%
“…Compared to plasma, erythrocytes are unique in blood. Erythrocytes are potential biocompatible vectors for different bioactive substances, including oligonucleotides [21,22]. Red blood cells have been successfully used to deliver modified oligonucleotides [23].…”
Section: Discussionmentioning
confidence: 99%
“…The system can regulate the biocompatibility of the erythrocytes and molecules on or in the erythrocytes, and thus prolong the bioavailability of the molecules in blood. Erythrocytes can also be used as a reservoir to allow slow release of drug or protein at a sustained therapeutic level [2,17,32]. Murciano et al [33] explored an innovative method in which tPA was coupled to the surface of erythrocytes and targeted the tPA-erythrocyte conjugate to blood clots.…”
Section: Discussionmentioning
confidence: 99%